Troubled Voyager’s gene therapy relaunch gets a boost with $630M Pfizer deal
It was spring, the pandemic seemed in retreat, patrons were filling Boston’s bars again and, in Cambridge, Voyager Therapeutics was in trouble.
The Third Rock-founded biotech emerged in 2014 as one of the first of the flashy new gene therapy companies, promising one-time treatments for common devastating conditions like Alzheimer’s. It was one of the first to deliver results, too: By 2017, its Parkinson’s treatment had improved motor function in 10 patients.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 119,800+ biopharma pros reading Endpoints daily — and it's free.